ES2380047T3 - Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca - Google Patents

Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca Download PDF

Info

Publication number
ES2380047T3
ES2380047T3 ES06736222T ES06736222T ES2380047T3 ES 2380047 T3 ES2380047 T3 ES 2380047T3 ES 06736222 T ES06736222 T ES 06736222T ES 06736222 T ES06736222 T ES 06736222T ES 2380047 T3 ES2380047 T3 ES 2380047T3
Authority
ES
Spain
Prior art keywords
poloxamer
composition
subject
myocytes
see
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06736222T
Other languages
English (en)
Spanish (es)
Inventor
Joseph Metzger
Dewayne Townsend
Soichiro Yasuda
Dan Michele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
University of Michigan-Ann Arbor
Original Assignee
University of Michigan (System)
University of Michigan-Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System), University of Michigan-Ann Arbor filed Critical University of Michigan (System)
Application granted granted Critical
Publication of ES2380047T3 publication Critical patent/ES2380047T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES06736222T 2005-02-25 2006-02-27 Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca Expired - Lifetime ES2380047T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65657005P 2005-02-25 2005-02-25
US656570P 2005-02-25
PCT/US2006/006862 WO2006091941A2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Publications (1)

Publication Number Publication Date
ES2380047T3 true ES2380047T3 (es) 2012-05-08

Family

ID=36928113

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06736222T Expired - Lifetime ES2380047T3 (es) 2005-02-25 2006-02-27 Composiciones y procedimientos para el tratamiento y prevención de la miocardiopatía y la enfermedad cardiaca

Country Status (8)

Country Link
US (2) US7846426B2 (enExample)
EP (1) EP1853280B1 (enExample)
JP (1) JP5042041B2 (enExample)
AT (1) ATE546147T1 (enExample)
AU (2) AU2006216420B2 (enExample)
CA (1) CA2599219C (enExample)
ES (1) ES2380047T3 (enExample)
WO (1) WO2006091941A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534843A (zh) * 2006-08-01 2009-09-16 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
WO2008124088A2 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009070793A1 (en) * 2007-11-29 2009-06-04 Pluromed, Inc. Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
EP2234625B8 (en) * 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US9867547B2 (en) 2012-11-29 2018-01-16 Siemens Healthcare Gmbh System and method to calculate cardiac characteristics
US20160067246A1 (en) * 2013-04-19 2016-03-10 Cedars-Sinai Medical Center Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
JP2016533377A (ja) * 2013-10-16 2016-10-27 マスト セラピューティクス インコーポレイテッドＭａｓｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 利尿薬によって誘発される血漿量の変化
AU2015287993B2 (en) 2014-07-07 2020-10-29 Liferaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3965734A4 (en) * 2019-05-06 2022-12-14 Arshintseva, Elena Valentinovna Method for increasing cancer patient's haemoglobin level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576612B1 (en) * 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
WO1992022202A1 (en) 1991-06-03 1992-12-23 Alpha Therapeutics Corporation Thrombolytic and perfluorochemical treatment for myocardial infraction
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS

Also Published As

Publication number Publication date
WO2006091941A2 (en) 2006-08-31
EP1853280A2 (en) 2007-11-14
JP5042041B2 (ja) 2012-10-03
CA2599219C (en) 2011-09-20
AU2010214636A1 (en) 2010-09-16
AU2006216420B2 (en) 2010-07-15
US7846426B2 (en) 2010-12-07
US20110044935A1 (en) 2011-02-24
CA2599219A1 (en) 2006-08-31
US8580245B2 (en) 2013-11-12
WO2006091941A3 (en) 2007-01-04
AU2006216420A1 (en) 2006-08-31
JP2008531598A (ja) 2008-08-14
ATE546147T1 (de) 2012-03-15
EP1853280B1 (en) 2012-02-22
US20080260681A1 (en) 2008-10-23
EP1853280A4 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
US8580245B2 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
AU2020323687B2 (en) MEK inhibitor for treatment of stroke
US20190224123A1 (en) O/w-emulsions comprising semifluorinated alkanes
RU2503453C2 (ru) Фармацевтические композиции, обладающие желаемой биодоступностью
ES2436781T3 (es) Composiciones y procedimientos de tratamiento y prevención de deficiencias de músculo esquelético
ES2673009T3 (es) Plataforma de suministro tópico de microemulsiones
ES2976358T3 (es) Composiciones farmacéuticas oftálmicas exentas de conservantes
US9155758B2 (en) Treatment of chronic progressive heart failure
BR112019012299A2 (pt) formulações farmacêuticas para o tratamento de glaucoma e métodos para a fabricação e uso das mesmas
ES2906262T3 (es) Composiciones para el tratamiento de la autodigestión
ES2728071T3 (es) Composiciones oftalmológicas y su uso
US20080200563A1 (en) Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors
ES2955158T3 (es) Composiciones y métodos de tratamiento de la distrofia muscular con antagonistas del receptor de tromboxano-A2
TW201521786A (zh) 胺碘酮類似物（ｂｕｄｉｏｄａｒｏｎｅ）調配物
BG64457B1 (bg) Фармацевтична форма за орално приложение, съдържаща hiv протеазен инхибитор
US20170022179A1 (en) Compositions, dosages, and methods of using tetrahydrocannabinol derivatives
WO2005037230A2 (en) Compositions and methods for treating heart failure
US20110212883A1 (en) Radical scavenger and active oxygen eliminating agent
RU2700416C1 (ru) Способ профилактики соматических осложнений в интра- и послеоперационном периоде у пациентов с эндопротезированием тазобедренного и коленного суставов
BR112017006057A2 (pt) composição farmacêutica a base de prostaglandina j2 incorporada em sistemas micelares baseados em poloxâmero para potencialização das atividades analgésica e anti-inflamatória
SK284244B6 (sk) Farmaceutický prostriedok na liečenie HIV infekcie na orálne podanie